Title:
FUSED RING HETEROARYL COMPOUNDS AS RIPK1 INHIBITORS
Document Type and Number:
WIPO Patent Application WO/2021/029632
Kind Code:
A1
Abstract:
The invention provides novel substituted heterocyclic compounds represented by Formula I, or a pharmaceutically acceptable salt, solvate, polymorph, ester, tautomer or prodrug thereof, and a composition comprising these compounds. The compounds provided can be used as inhibitors of RIPK1 and the therapeutic methods.
Inventors:
YOON CHEOLHWAN (KR)
BAE JONGHWAN (KR)
KIM NAMHEE (KR)
HAN CHEOLKYU (KR)
KIM MOONHWAN (KR)
SEO JEONGBEOB (KR)
BAE JONGHWAN (KR)
KIM NAMHEE (KR)
HAN CHEOLKYU (KR)
KIM MOONHWAN (KR)
SEO JEONGBEOB (KR)
Application Number:
PCT/KR2020/010513
Publication Date:
February 18, 2021
Filing Date:
August 09, 2020
Export Citation:
Assignee:
BISICHEM CO LTD (KR)
International Classes:
C07D413/12; A61K31/55; A61K31/553; A61P11/06; A61P25/28; A61P31/00; A61P35/00; C07D403/12; C07D487/04; C07D498/04
Domestic Patent References:
| WO2017136727A2 | 2017-08-10 | |||
| WO2016027253A1 | 2016-02-25 | |||
| WO2018007973A2 | 2018-01-11 |
Foreign References:
| CN109134448A | 2019-01-04 |
Other References:
PHILIP A HARRIS; SCOTT B BERGER; JAE U JEONG; RAKESH NAGILLA; DEEPAK BANDYOPADHYAY; NINO CAMPOBASSO; CAROL A CAPRIOTTI; JULIE A CO: "Discovery of a First-in-Class Receptor Interacting Protein 1 (RIP1) Kinase Specific Clinical Candidate (GSK2982772) for the Treatment of Inflammatory Diseases", JOURNAL OF MEDICINAL CHEMISTRY, vol. 60, no. 4, 23 February 2017 (2017-02-23), pages 1247 - 1261, XP055448328, ISSN: 0022-2623, DOI: 10.1021/acs.jmedchem.6b01751
See also references of EP 4010340A4
See also references of EP 4010340A4
Attorney, Agent or Firm:
LEE, Jong-Seung (KR)
Download PDF: